Search
for
Sort by
Research 61–90 of 309
- Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
- Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
- Determining meaningful thresholds for evaluating treatment efficacy in patients with alopecia areata
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Mesenchymal stem/stromal cell therapy in atopic dermatitis and chronic urticaria: immunological and clinical viewpoints
- Real-world evidence in alopecia areata treatment: A narrative review
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- Unlocking the Potential of Rosemary in Alopecia: A Narrative Review of Evidence on Mechanism, Applications and Challenges
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Janus kinase inhibitors for alopecia areata: A narrative review
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Alopecia areata: current concepts
- Alopecia Areata: Pathogenesis, current treatments, and future perspectives
- Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
- Alopecia in Children
- Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
- Mucocutaneous reactions to chemotherapy
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
- Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata
- Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
- Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
- Ritlecitinib: First Approval
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews
- Genetic Variation in the Human Androgen Receptor Gene Is the Major Determinant of Common Early-Onset Androgenetic Alopecia